Loxo Oncology, Inc
LOXO
LOXO was delisted on the 14th of February, 2019.
1 hedge funds and large institutions have $65K invested in Loxo Oncology, Inc in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 231 closing their positions.
100% less funds holding
Funds holding: 232 → 1 (-231)
100% less funds holding in top 10
Funds holding in top 10: 7 → 0 (-7)
100% less capital invested
Capital invested by funds: $4.15B → $65K (-$4.15B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 231
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$391M |
| 2 |
BlackRock
New York
|
-$319M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$296M |
| 4 |
AC
Aisling Capital
New York
|
-$286M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$280M |
LOXO Hedge Fund Activity: Q1 2019 in Review
1 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q1 2019, worth a combined $65K — down 100% from $4.15B a quarter earlier.
Sellers outnumbered buyers: 231 funds closed out of LOXO and 0 opened new positions — a net loss of 231 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $391M sold.
- 1 institutional investor held Loxo Oncology, Inc (LOXO) as of Q1 2019, down from 232 in Q4 2018.
- Funds reported $65K of Loxo Oncology, Inc stock for Q1 2019, down 100% quarter-over-quarter.
- 0 funds opened new Loxo Oncology, Inc positions in Q1 2019 and 231 closed out, a net change of -231 holders.
- The largest Loxo Oncology, Inc seller in Q1 2019 was Vanguard Group, an estimated $391M sold.
Based on aggregated 13F filings for Q1 2019.